On 18 June 2019, Lonza will host a free 60-minute webinar on mycoplasma contamination and how Lonza’s MycoAlert™ Assay enables simple and fast detection of mycoplasma contaminants in cell cultures.
Mycoplasma contamination of cell cultures can be detrimental to the reliability, reproducibility and consistency of experimental results. However, despite the severe consequences, mycoplasma contamination is often overlooked, especially since mycoplasma are not visible to the naked eye, even at high concentrations. As such, they may remain undiscovered for months. Regular testing of cell cultures is thus key to minimize the contamination potential.
Titled “Know Your Enemy: Mycoplasma Contamination in Cell Culture,” the webinar will be presented by Isabella Drewelus, Scientific Support Specialist at Lonza. During the webinar, she will discuss:
What mycoplasma are and how they get into cell cultures
The potential impact of mycoplasma on cells and the generated scientific data
How Lonza’s MycoAlert™ Assay facilitates quick and simple detection of mycoplasma contamination in cell cultures
More information about attending the webinar is available here.
Date: Tuesday, 18 June, 2019
8 AM PDT (Los Angeles)
11 AM EDT (New York)
4 PM BST (London)
5 PM CEST (Berlin)
Further information can be found on Lonza’s Mycoplasma Contamination application page. By registering interest in the webinar, participants will also receive a link once it is available to view “on demand” via the Lonza website.
More information about Lonza’s upcoming and on-demand webinars is available via www.lonza.com/webinars.
Lonza is an integrated solutions provider that creates value along the Healthcare Continuum®. Through our Pharma & Biotech segment and our Specialty Ingredients segment businesses, we harness science and technology to serve markets along this continuum. We focus on creating a healthy environment, promoting a healthier lifestyle and preventing illness through consumers’ preventive healthcare, as well as improving patient healthcare by supporting our customers to deliver innovative medicines that help treat or even cure severe diseases.
Patients and consumers benefit from our ability to transfer our pharma know-how to the healthcare, hygiene and fast-moving consumer goods environment and to the preservation and protection of the world where we live.
Founded in 1897 in the Swiss Alps, Lonza today is a well-respected global company with more than 100 sites and offices and approximately 15,500 full-time employees worldwide at the end of 2018. The company generated sales of CHF 5.5 billion in 2018 with a CORE EBITDA of CHF 1.5 billion. Further information can be found at www.lonza.com